H.C. Wainwright has reiterated its Buy rating on Brainsway (NASDAQ: BWAY), the medical device company focused on non-invasive brain stimulation technology. The analyst note, published this week, reaffirms confidence in the firm's deep transcranial magnetic stimulation (Deep TMS) platform, which is used to treat major depressive disorder, obsessive-compulsive disorder, and other neurological conditions.
Brainsway's shares have seen periodic volatility over the past year, but the reiterated rating suggests analysts see long-term value in the company's pipeline and commercial partnerships. The stock trades on the NASDAQ and is not directly listed on the FTSE, though it may be held within some UK-focused healthcare or thematic funds.
For UK investors and pension holders, the reiteration highlights ongoing interest in the medtech sector, particularly in mental health and neurology. Brainsway's technology has received regulatory clearances in the US and Europe, including CE marking, which allows marketing across the European Economic Area. The company has also expanded its presence through distribution agreements in several international markets.
Analysts at H.C. Wainwright have not altered their price target or underlying assumptions with this reiteration, indicating a stable outlook for the near term. The broader medtech sector has faced headwinds from supply chain pressures and shifting healthcare budgets, but Brainsway's niche in non-invasive brain stimulation could offer resilience if clinical adoption continues to grow.
No specific price target or financial forecasts were disclosed in the reiteration. Brainsway is expected to report its next quarterly earnings in the coming weeks, which may provide further clarity on revenue trends and operational performance.